Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJordan CarterMCMichael CookSSStephen J. Schuster

Discussion

Loading...

Member takes

Overview

Observational analysis shows sustained progression-free survival in younger mantle cell lymphoma patients receiving BTK inhibitors, suggesting a viable frontline strategy.

Key Points

  • Overall, 80% of patients experienced adverse events related to BTK inhibitors, with common occurrences being bleeding and infections.
  • Younger patients treated with second-generation BTK inhibitors had a median progression-free survival of 52% compared to 48% for those receiving chemotherapy.
  • Analysis of cohort outcomes reveals significant safety and efficacy of BTK inhibitors as initial treatment for mantle cell lymphoma.
  • Findings may enable future guidelines on the use of BTK inhibitors in younger patients with mantle cell lymphoma.

Cite This Study

Carter et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d715https://doi.org/10.1182/blood-2025-7119
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy2025
  2. 2Real-world treatment patterns, patient characteristics, and outcomes of cbtki-based therapies amongst a contemporary cohort of patients with R/R MCL in the United States2025
  3. 3Efficacy and safety of zanubrutinib-containing regimens in patients with newly diagnosed Mantle Cell Lymphoma: Interim results from a Phase II investigator-initiated study2025
  4. 4Initial treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma in the era of BTK inhibitors: A multicenter real-world study2025
  5. 5Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study2025 · 1 citations